In the same cohort high CD163+/CD68+ ratio in the tumor front, but not in tumor stroma, was closely correlated with enhanced lymphovascular invasion, tumor invasion, and TNM stage as well as recurrence-free survival (RFS) and OS of patients with CRC. The gene discussed is CD68; the disease is neoplasm.